RecruitingNot ApplicableNCT06793059
Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)
Sponsor
Jacobs institute
Enrollment
10 participants
Start Date
Jan 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms
Eligibility
Min Age: 22 Years
Inclusion Criteria1
- Adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments.
Exclusion Criteria1
- Cannot provide consent or legally authorized representative not available to provide consent Criteria:
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICESHIELD
Pipeline SHIELD device under study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06793059
Related Trials
Cera™ Vascular Plug System Post-Market Clinical Follow-Up
NCT060990154 locations
Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment
NCT063527101 location
Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm
NCT028789671 location
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
NCT068726843 locations
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
NCT026387011 location